Found 0 matching trials
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma PHASE2 RATIONALE: Bortezomib and thalidomide may stop the growth of multiple myelo...
Show More Location
City of Hope Medical Center
Learn More & Join Trial
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma PHASE2 Background:
Advanced urothelial cancer has no cure. But only a few chemoth...
Show More Location
National Institutes of Health Clinical Center
Learn More & Join Trial
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients PHASE2 An unrandomized phase 2 study of selinexor in combination with lenalidomide...
Show More Status
Active Not Recruiting
Location
Aalborg University Hospital
Learn More & Join Trial
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma NA This clinical trial studies peripheral blood hemapoietic stem cell mobiliza...
Show More Location
Barbara Ann Karmanos Cancer Institute
Learn More & Join Trial
Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer PHASE2 This study is conducting an evaluation of two chemotherapy drugs, Velcade a...
Show More Location
Women & Infants' Hospital
Learn More & Join Trial
Safety and Efficacy Assessments of Osalmid in Multiple Myeloma PHASE1 This study aims to evaluate the safety and efficacy of a traditional cholag...
Show More Location
Shanghai 10th People's Hospital
Learn More & Join Trial
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation PHASE1 Primary Objectives:
* VCDI cohort:
* To determine the maximum tolerated...
Show More Location
Investigational Site Number : 250002
Learn More & Join Trial
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma PHASE3 The purpose of the study is to determine the best treatment approach based ...
Show More Location
Beth Israel Deaconess Medical Center (BIDMC)
Learn More & Join Trial
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma PHASE2 RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some o...
Show More Location
University of California Los Angeles
Learn More & Join Trial
Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma PHASE2 The purpose of this study is to improve efficacy of treatment for patients ...
Show More Location
Mannheimer Onkologie Praxis
Learn More & Join Trial